Form 4: Moleculin Biotech CEO Walter Klemp Reports Stock Transactions
SEC Form 4 Filing
Walter Klemp, CEO and President of Moleculin Biotech, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On June 22, 2024, Walter Klemp, CEO and President of Moleculin Biotech, reported transactions involving the company's stock.
- Klemp acquired 8,990 shares of common stock through the vesting of restricted stock units.
- Additionally, 2,190 shares were disposed of at a price of $3.74 for payment of taxes related to the vesting of restricted stock units.
- Following these transactions, Klemp directly owns 56,293 shares of common stock.
- Klemp also owns 114,134 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard SEC filing reporting stock transactions. There is no indication of positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to investors regarding the actions of company executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely minimal as it involves a relatively small number of shares.
Key Dates
| Date | Description |
|---|---|
| 06/22/2023 | Reporting person was granted 35,959 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 06/22/2024 | Date of stock transactions: acquisition of 8,990 shares via restricted stock units and disposal of 2,190 shares for tax purposes. |
| 06/25/2024 | Date of signature for the report. |
Keywords
Moleculin Biotech, MBRX, Walter Klemp, CEO, Stock Transactions, Form 4, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.